BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release19-10-2023
19-10-2023
Biocon slumps 4% after US FDA red flags Malaysia unit
The official action indicated or an "OAI" classification of the insulin unit by the FDA can delay or withhold approvals for products manufactured at the facility18-10-2023
BIOCON LTD. - 532523 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended September 30, 2023.16-10-2023
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Schedule of Investor Meeting13-10-2023
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of schedule of meeting with Analyst/Institutional Investor on- 1. October 12, 2023- In-person 2. October 13, 2023- In person 3. October 16, 2023- In person, 1x1 and group meetings 4. October 17, 2023- In person, 1x1 and group meetings11-10-2023
BIOCON LTD. - 532523 - Investor Meeting
Meeting conducted with Institutional Investors/Research Analysts11-10-2023
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Change in Management
Change in Senior Management Personnel (SMP) of the Company.09-10-2023
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Conference Call for analysts and investors on November 10, 2023.09-10-2023
BIOCON LTD. - 532523 - Board Meeting Intimation for Quarter And Half Year Ended September 30, 2023.
BIOCON LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/11/2023 ,inter alia, to consider and approve un-audited standalone and consolidated financial results for the quarter and half year ended September 30, 2023, amongst other routine matters.09-10-2023